Banner - NPPA Connect

Opinion|Videos|September 25, 2024

Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Author(s)Pearl Grimes, MD, FAAD

Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.

Episodes in this series

EP. 1 Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP. 1 Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP. 2 Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP. 2 Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP. 3 Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP. 3 Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP. 4 Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

EP. 4 Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

10 Skin Cancer Exam Tips

Dermatology Times Conferences & Meetings Calendar: September 2026

Early Recognition and Psychosocial Impact in Male Pattern Hair Loss